Picture of Can Fite Biopharma logo

CANF Can Fite Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-0.82%
3m-4.71%
6m-29.11%
1yr-46.94%
Volume Change (%)
10d/3m-83.18%
Price vs... (%)
52w High-37.63%
50d MA+0.89%
200d MA-14.76%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-135.71%
Return on Equity-142.16%
Operating Margin-1203.06%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Can Fite Biopharma EPS forecast chart

Profile Summary

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
September 11th, 1994
Public Since
September 22nd, 2005
No. of Employees
8
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
1,497,128,493
Blurred out image of a map
Address
26 Ben Gurion Street, RAMAT GAN, 5257346
Web
https://www.canfite.com/
Phone
+972 39241114
Auditors
Kost, Forer, Gabbay & Kasierer

CANF Share Price Performance

Upcoming Events for CANF

Similar to CANF

Picture of cbdMD logo

cbdMD

us flag iconNYSE MKT

Picture of CEL-SCI logo

CEL-SCI

us flag iconNYSE MKT

Picture of iBio logo

iBio

us flag iconNYSE MKT

FAQ